9amHealth Raises $26M Series B to Expand AI-Driven Virtual Specialty Care
Virtual chronic care platform 9amHealth has raised $26 million in Series B funding to expand beyond cardiometabolic care into broader high-cost chronic conditions. The company says its platform has already generated more than $50 million in projected medical and pharmacy savings across two Fortune 100 employers.
FUNDRAISE
Editor
5/18/20261 min read
9amHealth has raised $26 million in Series B funding to expand its AI-enabled virtual specialty care platform for chronic conditions. The round was led by Define Ventures, with participation from SemperVirens, Catalio Capital Management, and NewHealth Ventures. As part of the investment, Define Ventures Founder and Managing Partner Lynne O’Keefe will join the company’s board.
The company initially focused on obesity, diabetes, and hypertension management, but is now expanding into additional specialty chronic conditions that drive a growing share of employer healthcare costs. According to the company, these conditions account for up to 70% of employer pharmacy spend.
9amHealth combines virtual specialty care with at-home lab testing, medication management, and AI-supported clinical workflows. Members receive access to endocrinologists, obesity medicine specialists, and clinical pharmacists through a 24/7 care model designed for employers, health plans, and pharmacy benefit managers.
CEO and co-founder Frank Westermann said the company’s existing clinical and technology infrastructure allows it to scale care delivery across increasingly complex conditions while maintaining operational efficiency.
The company also stated that its platform has produced more than $50 million in projected medical and pharmacy savings across two Fortune 100 employers, driven in part by growing demand for GLP-1 therapies and specialty chronic care management.